Could Ultrasound-Based Radiomics Noninvasively Predict Axillary Lymph Node Metastasis in Breast Cancer?

Xiaoying Qiu, MD, Yongluo Jiang, MD, Qiyu Zhao, MD, Chunhong Yan, MM, Min Huang, MM, Tian’an Jiang, MD

Objectives—This work aimed to investigate whether quantitative radiomics imaging features extracted from ultrasound (US) can noninvasively predict breast cancer (BC) metastasis to axillary lymph nodes (ALNs).

Methods—Presurgical B-mode US data of 196 patients with BC were retrospectively studied. The cases were divided into the training and validation cohorts (n = 141 versus 55). The elastic net regression technique was used for selecting features and building a signature in the training cohort. A linear combination of the selected features weighted by their respective coefficients produced a radiomics signature for each individual. A radiomics nomogram was established based on the radiomics signature and US-reported ALN status. In a receiver operating characteristic curve analysis, areas under the curves (AUCs) were determined for assessing the accuracy of the prediction model in predicting ALN metastasis in both cohorts. The clinical value was assessed by a decision curve analysis.

Results—In all, 843 radiomics features per case were obtained from expert-delineated lesions on US imaging in this study. Through radiomics feature selection, 21 features were selected to constitute the radiomics signature for predicting ALN metastasis. Area under the curve values of 0.778 and 0.725 were obtained in the training and validation cohorts, respectively, indicating moderate predictive ability. The radiomics nomogram comprising the radiomics signature and US-reported ALN status showed the best performance for ALN detection in the training cohort (AUC, 0.816) but moderate performance in the validation cohort (AUC, 0.759). The decision curve showed that both the radiomics signature and nomogram displayed good clinical utility.

Conclusions—This pilot radiomics study provided a noninvasive method for predicting presurgical ALN metastasis status in BC.

Key Words—axillary lymph node metastasis; breast cancer; presurgical prediction; radiomics; ultrasound

B reast cancer (BC) represents one of the most common malignancies and the deadliest cancer in women. About 98.6% of women survive for 5 years on diagnosis of localized BC. However, this rate is reduced to 84.4% in cases of regional lymph node metastasis (LNM). The axillary lymph node (ALN) status constitutes the most important independent prognostic factor for predicting disease-free survival as well as overall survival in patients with BC.

Clinically, the diagnosis of ALN involvement in BC is determined by sentinel lymph node biopsy and axillary lymph node
dissection (ALND), which is an important treatment option for invasive BC. It is noteworthy that both techniques are invasive, which might result in a cohort of complications to various extents. Indeed, ALND causes lymphedema, infection, shoulder motion restriction, and major vessel and nerve injuries due to the aggressiveness and extensiveness of surgery. 4,5 Meanwhile, as an alternative to conventional ALND, sentinel lymph node biopsy is associated with less-extensive complications, including abnormal function, nerve injury, lymphedema, and upper arm numbness. 6,7 Furthermore, whether lymph node–negative patients could benefit from ALND remains largely unclear. 8,9 Therefore, accurate preoperative identification of the ALN status could facilitate clinical decision making, and noninvasive assessments of the ALN status in BC is attracting growing attention.

**Materials and Methods**

**Patients**

This study had approval from the Institutional Review Board of the First Affiliated Hospital, College of Medicine, Zhejiang University Hospital, which waved the requirement for informed consent. A total of 256 Chinese women with invasive BC (confirmed by pathology) were recruited from January 2017 to March 2018 in our center. Inclusion criteria were as follows: (1) overt lesion on preoperative US images; (2) histopathologically confirmed BC in the surgical specimen; and (3) lymph node status assessed by sentinel lymph node biopsy and ALND. Exclusion criteria were as follows: (1) preoperative radiotherapy, chemotherapy, or endocrine therapy; (2) neoadjuvant chemotherapy before surgery; and (3) contralateral or multifocal breast tumors. Ultimately, 196 lesions were analyzed, including 21 (10.7%) triple-negative, 22 (11.2%) human epidermal growth factor receptor 2 (HER2)–enriched, 41 (20.9%) luminal A, and 112 (57.7%) luminal B lesions.

**Ultrasound Examination and US-Reported ALN Status**

All patients were examined with a MyLab Twice scanner (Esaote SpA, Genoa, Italy) using a 5–13-MHz LAS23 transducer, a LOGIQ E9 scanner (GE Healthcare, Chicago, IL) using 6–13-MHz linear transducer, an iU22 scanner (Philips Healthcare, Andover, MA) using a 5–12-MHz L12-5 transducer, and an Acuson S2000 scanner (Siemens Medical Solutions, Mountain View, CA) using a 5.5–18-MHz L6 HD transducer. All images were collected by an image archiving and communication system and interpreted by 2 breast radiology experts (10 years of experience) in an independent fashion. Any discrepancy was resolved by consensus.
College of Radiology Breast Imaging Reporting and Data System for US. An ALN was believed to be positive for suspicious metastasis when it had one of the following characteristics: irregular cortical thickness of greater than 3 mm, longest-to-shortest axis ratio of less than 2, or absence of a fatty hilum.

Feature Extraction

All US images in the Digital Imaging and Communications in Medicine format were acquired and imported into 3D Slicer version 4.8.1 software (Brigham and Women’s Hospital, Boston, MA) one by one. The regions of interest of the image focus were delineated in the largest sectional area by a radiologist with 10 years of clinical experience with using the Segment Editor platform integrated in the 3D Slicer. An example of BC lesion delineation is shown in Figure 1.

The image texture features were extracted on the PyRadiomics platform (https://github.com/Radiomics/pyradiomics) integrated in the 3D Slicer. Wavelet transform was used to analyze the spatial time-frequency of the obtained 2-dimensional images, which were divided into 8 subimages: HHH, HLL, HLH, HHL, LLH, LHL, LHH, and LLL. Finally, there were 843 radiomics features for each case from the expert-delineated lesions on the original US images and 8 wavelet transform sub-images. The feature categories included shape, first-order, gray-level co-occurrence matrix, gray-level size zone matrix, gray-level distance zone matrix, neighborhood gray-tone difference matrix, and gray-level run length matrix.

Feature Selection and Radiomics Model Generation

Forty-six nodules were randomly selected from the total sample for region of interest segmentation and feature extraction once more by the same radiologist and a different one. Interclass correlation coefficients were used to assess interobserver agreement for feature extraction. Then random sampling in the training and validation sets (ratio approximating 7:3) was performed. The training cohort was used to select features and generate the prediction model. The elastic net logistic regression algorithm, a combination of the lasso and ridge regression approaches, was used for selecting the most efficient predictive indices with nonzero coefficients from among the obtained texture features with good reproducibility by adjusting the coefficients λ and α. A model generated via elastic net regression was the linear weighted sum of the chosen radiomics features. The most useful predictive features retained helped build a logistic regression model for predicting ALN metastasis in patients with BC. The associations between ALN metastasis and the BC lesion Breast Imaging Reporting and Data System category, clinical factors (including age, childbearing history, menopause history, and family history), and US-reported ALN metastasis were then examined using the logistic regression model.
status were assessed by univariate analyses. The factors with $P < .05$ in the univariate analyses were incorporated with the radiomics signature to build a radiomics nomogram as a quantitative tool to predict ALN metastasis using a stepwise selection logistic regression analysis. In a receiver operating characteristic (ROC) curve analysis, the predictive accuracy was assessed by determining the area under curve (AUC) in the training cohort.

Validation and Clinical Utility of the Prediction Model
The generated prediction model was further verified in the validation cohort on the basis of the thresholds found in the training cohort. The relevant AUC was also calculated. A decision curve analysis was performed to assess the clinical utility of the newly developed model, and net benefits at various threshold probabilities were quantified in the training set.

Statistical Analysis
R version 3.5.1 statistical software (R Foundation for Statistical Computing, Vienna, Austria) was used for the statistical analysis. An elastic net logistic regression analysis was performed with the glmnet package. Nomogram construction was performed with the rms package. Receiver operating characteristic curve generation was performed with the pROC package, which was compared by the DeLong test. The decision curve analysis was performed with the rmda package. Bilateral $P < .05$ indicated statistical significance.

Results
Patient Features
Table 1 summarizes the features of BC cases in both training and validation sets. The training cohort ($n = 141$; mean age $\pm$ SD, $53.35 \pm 10.97$ years) included 18 (12.8%) triple-negative, 13 (9.2%) HER2-positive, 26 (18.4%) luminal A, and 84 (59.6%) luminal B lesions. The validation cohort ($n = 55$; mean age, $53.35 \pm 12.15$ years) included 3 (5.5%) triple-negative, 9 (16.4%) HER2-positive, 14 (25.5%) luminal A, and 29 (52.7%) luminal B lesions. Both sets had comparable ALN prevalence rates ($P = .107$). Axillary lymph node metastasis positivity rates were 31.9% and 45.5% in the training and validation cohorts, respectively.

Radiomics Features
In all, 843 features were obtained from US images that masked the selected lesions. Among these features, 626 showing an interclass correlation coefficient of greater than 0.75 were used for the subsequent analysis. A total of 21 parameters (Table 2) with non-zero coefficients were chosen by using the elastic net logistic regression model in the training cohort (Figure 2).

Performance of the Radiomics Classifier
A nomogram was constructed with the US-reported ALN status and radiomics signature (Figure 3). The AUC values were higher for both the radiomics signature and nomogram for predicting ALN metastasis (AUC, 0.816 [95% confidence interval (CI), 0.740–0.891]; and 0.778 [95% CI, 0.659–0.861], respectively), than that of the US-reported ALN status alone (AUC, 0.626 [95% CI, 0.541–0.711], $P < .001$).
CI, 0.549–0.703]; P < .001) in the training cohort. However, there was no significant difference between the radiomics signature and nomogram (P < .001) in the training cohort, and there was no statistical difference in accuracy among the 3 models (AUC, 0.759 [95% CI, 0.629–0.889]; 0.725 [95% CI, 0.588–0.863]; and 0.687

Table 2. List of the Selected Features With Nonzero Coefficients

| Image Type | Feature Class | Feature Name                                           | Coefficient    |
|------------|---------------|--------------------------------------------------------|----------------|
| Wavelet.HHH | GLCM          | JointEntropy                                           | 6.606913619    |
| Wavelet.HHH | GLCM          | JointEnergy                                            | −10.61526552   |
| Wavelet.HLL | GLSZM         | GrayLevelVariance                                     | 0.091019657    |
| Wavelet.HLL | GLSZM         | GrayLevelNonUniformityNormalized                      | −0.043373295    |
| Wavelet.HLL | GLSZM         | SizeZoneNonUniformityNormalized                       | −0.028913255    |
| Wavelet.HLL | GLSZM         | GrayLevelNonUniformity                                | 0.002582036     |
| Wavelet.HLL | GLSZM         | HighGrayLevelZoneEmphasis                             | 0.115264983     |
| Wavelet.HLL | GLSZM         | LowGrayLevelZoneEmphasis                              | −0.452924866    |
| Wavelet.LHL | GLDM          | DependenceVariance                                    | 0.126561699     |
| Wavelet.LHL | GLSZM         | SizeZoneNonUniformity                                 | 0.001372282     |
| Wavelet.LHL | GLSZM         | GrayLevelNonUniformity                                | 0.001874068     |
| Wavelet.LHL | NGTDM         | Strength                                               | −0.190068297    |
| Wavelet.LHH | GLDM          | DependenceEntropy                                     | −0.281946732    |
| Wavelet.LHH | GLDM          | SmallDependenceEmphasis                               | 4.763295426     |
| Wavelet.LHH | GLCM          | Imc1                                                  | 0.787816784     |
| Wavelet.LHH | GLRLM         | SmallDependenceHighGrayLevelEmphasis                  | 0.713537119     |
| Wavelet.LLL | GLDM          | LargeDependenceLowGrayLevelEmphasis                   | 0.010883966     |
| Wavelet.LLL | GLDM          | LargeDependenceLowGrayLevelEmphasis                   | 0.036722449     |
| Wavelet.LLL | GLRLM         | LongRunLowGrayLevelEmphasis                           | 0.073736589     |
| Wavelet.LLL | GLSZM         | SizeZoneNonUniformity                                 | 0.000651089     |
| Wavelet.HHL | First-order   | Skewness                                               | −0.108971155    |

GLCM indicates gray-level co-occurrence matrix; GLDM, gray-level distance zone matrix; GLRLM, gray-level run length matrix; GLSZM, gray-level size zone matrix; and NGTDM, neighborhood gray-tone difference matrix.

Figure 2. Selection of texture features by the elastic net logistic regression model. α = 0.5. A, Tuning index (λ) selection in the elastic net model used 10-fold cross-validation based on minimum criterion. An ROC curve was plotted against log λ. Dotted vertical lines indicate optimal values based on minimum criterion and 1 SE of the minimum criterion. λ = 0.076 (log λ = −2.575) was selected (minimum criterion). B, Elastic net coefficients of the 626 texture features. Coefficients were plotted against log λ values. The vertical line was plotted at the value obtained by the above 10-fold cross-validation. A total of 21 resulting features showing nonzero coefficients are indicated.
[95% CI, 0.577–0.796]; \( P > .001 \)) in the validation cohort. The predictive performances for discriminating ALN metastasis, as determined by ROC curves, are shown in Figure 4.

**Clinical Value of the Prediction Model**

The decision curve analyses based on the US-reported ALN status, radiomics signature, and radiomics

**Figure 3.** A radiomics nomogram was developed with the US-reported ALN status and radiomics signature for the prediction of ALN metastasis in the primary cohort.

| Points | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |
|--------|---|----|----|----|----|----|----|----|----|----|-----|

R

| 0.250 | 0.500 | 0.750 | 0.85 | 0.95 | 0.99 | 0.999 |

Total Points

| 0.050 | 0.1 | 0.250 | 0.500 | 0.750 | 0.85 | 0.95 | 0.99 | 0.999 |

Risk of LN metastasis

**Figure 4.** Receiver operating characteristic curves of each model for predicting ALN metastasis in the training and validation sets.

**Figure 5.** Decision curve analysis for each model in predicting ALN metastasis. The net benefit is depicted on the y-axis. The gray and black lines represent a situation in which all cases hypothetically have ALN metastasis and a situation in which no cases hypothetically have ALN metastasis, respectively. A threshold probability of 0.04 to 0.77 was obtained, and the net benefit of using the developed radiomics signature (red curve) for predicting ALN metastasis was more considerable than that of the treat-all or treat-none approach. If the threshold probability is greater than 0.03, then using the radiomics nomogram (blue curve) to predict ALN metastasis adds more benefit for patients than that of the treat-all or treat-none scheme.
nomogram are depicted in Figure 5. The net benefit of applying the newly developed radiomics nomogram for predicting ALN metastasis achieved the most clinical utility when the threshold probability for a patient was greater than 0.03.

Discussion

This work used radiomics based on US, which is used in BC screening and diagnosis more widely than radiography and magnetic resonance imaging in China, to assess associations of BC ALN metastasis with radiomics features. The outcomes reported in this are promising. We identified 21 texture features derived from US of primary tumors for predicting ALN metastasis in BC, with AUC values of 0.778 and 0.725 in the training and validation sets, respectively. Integrated with the US-reported ALN status, the radiomics nomogram could not further improve its predictive accuracy for ALN metastasis, with AUC values of 0.816 and 0.759 in the training and validation sets. Patients could obtain a pronounced net benefit from these 3 models compared with the treat-all or treat-none scheme. However, the radiomics nomogram achieved the most clinical utility to predict ALN metastasis when the threshold probability for a patient was greater than 0.03.

The ALN status is of great importance to staging, treatment, and prognosis in BC and also represents one of the most important reference indicators for postoperative radiotherapy and chemotherapy.31 It plays a critical role in the development of personalized treatment plans for BC cases. Klar et al32 designed the Memorial Sloan-Kettering Cancer Center nomogram based on 3786 cases undergoing lymph node biopsy, with an AUC of 0.754 in determining the odds of LNM. Additionally, many works33–36 have generated multivariate models to predict LNM referring to clinicopathologic data. However, clinicopathologic data can only be obtained after surgery and an immunohistochemical examination. Clinically, there is a great and increasing need for accurate and noninvasive methods for predicting preoperative ALN metastasis. Compared with previous clinicopathologic reports, this work had the advantage that ALN metastasis could be assessed preoperatively and in a noninvasive fashion.

Some related research has shown that pathologic features of primary tumors can predict ALN metastasis in BC.8,33 Thus, the quantitative image features of primary tumors could also be used for predicting ALN metastasis. Previously, a few reports could predict the LNM status in BC using radiomics features obtained from primary tumors, with good accuracy (AUC values ranging from 70.99% to 89.54%).37–42 In some of these studies, multivariate models were generated to predict LNM on the basis of the radiomics signature and clinical data. In this study, a radiomics signature was generated solely on the basis of features extracted from the US images of primary tumors. As shown above, the radiomics signature was effective in predicting ALN metastasis. Moreover, this method only relied on US, which is widely used for BC diagnosis; therefore, it may serve as a routine checkup tool for BC.

Yu et al42 also used the radiomics features extracted from US images to construct a nomogram to predict axillary LNM in early-stage invasive BC with a larger data set (426 patients). The radiomics signature, which consisted of 14 selected ALN status–related features, achieved moderate prediction efficacy, with AUCs of 0.78 and 0.71 in the primary and validation cohorts, respectively, and the radiomics nomogram comprising the tumor size, US-reported ALN status, and radiomics signature achieved better predictive efficacy (AUC, 0.84 and 0.81 in the primary and validation cohorts). The results were similar to our results. In their study, only early tumor cases were selected, and 96 radiomics features were extracted, whereas in our study, cases included advanced tumors, which expanded the range of the tumor stage. Wavelet transform was used to analyze the spatial time-frequency of the obtained 2-dimensional images, and finally, a total of 843 radiomics features were extracted, which greatly expanded the feature dimension.

The development of radiomics has very important clinical application prospects. It also brings new opportunities for the prediction of ALN metastasis in BC. The number of features extracted from medical images is usually dozens, hundreds, or even thousands. There is feature repeatability between different image categories, so redundancy needs to be removed. However, there is no unified standard to eliminate redundancy, so the view that the more parameters, the better may be misleading. Radiomics data usually characterized by a small sample size and large variable size would increase the overfitting in classification, theoretically leading to deception of the diagnostic results of some training data, which may not be extended to the new
test data. At present, the research on ALN metastasis prediction by radiomics based on US images is still in its infancy. Its prediction efficiency has not reached the ideal state, so the model needs to be further optimized.

The limitations of this study should be mentioned. Firstly, the sample size was relatively small. Second, the features extracted in this study were based on a single section per case, and their value was used to represent the whole 3-dimensional lesion. Third, this was a retrospective analysis of breast US images from a single center. There is still a long way to go before ALN metastasis can be predicted by radiomics analysis based on breast US. Further studies assessing large multicenter cohorts with standardized 3-dimensional image acquisition tools are needed.

In conclusion, this pilot radiomics study provided an accurate and noninvasive method for predicting the presurgical ALN metastasis status in BC, which is very important in guiding treatment and avoiding needless invasive removal of lymph nodes.

References

1. Antunovic L, Gallivanone F, Sollini M, et al. [18F]FDG PET/CT features for the molecular characterization of primary breast tumors. Eur J Nucl Med Mol Imaging 2017; 44:1945–1954.
2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64:252–271.
3. Kolarik D, Pecha V, Skovajsova M, et al. Predicting axillary sentinel node status in patients with primary breast cancer. Neoplasma 2013; 60:334–342.
4. Sakorafas GH, Peros G, Cataliotti L, Vlastos G. Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol 2006; 15:153–165.
5. Warmuth MA, Bowen G, Prosnitz LR, et al. Complications of axillary lymph node dissection for carcinoma of the breast. Cancer 1998; 83:1362–1368.
6. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006; 13:491–500.
7. Mansel R, Goyal A, Newcombe R. Objective assessment of lymphedema, shoulder function and sensory deficit after sentinel node biopsy for invasive breast cancer: ALMANAC trial [abstract]. Breast Cancer Res Treat 2004; 88:S12.
8. Zarella MD, Breen DE, Reza A, Milutinovic A, Garcia PU. Lymph node metastasis status in breast carcinoma can be predicted via image analysis of tumor histology. Anal Quant Cytopathol Histopathol 2015; 37:273–285.
9. Garcia-Etienne CA, Ferrari A, Della Valle A, et al. Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: an evidence-based update in a European breast center. Eur J Surg Oncol 2020; 46:15–23.
10. Fung AD, Collins JA, Campassi C, Ioffe OB, Staats PN. Performance characteristics of ultrasound-guided fine-needle aspiration of axillary lymph nodes for metastatic breast cancer employing rapid on-site evaluation of adequacy: analysis of 136 cases and review of the literature. Cancer Cytopathol 2014; 122:282–291.
11. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016; 278:563–577.
12. Lambin P, Ruis-Velazquez E, Leijenaar R, et al. Radiomics: extending more information from medical images using advanced feature analysis. Eur J Cancer 2012; 48:441–446.
13. Lambin P, Leijenaar RT, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017; 14:749–762.
14. Luo WQ, Huang QX, Huang XW, Hu HT, Zeng FQ, Wang W. Predicting breast cancer in breast imaging reporting and data system (BI-RADS) ultrasound category 4 or 5 lesions: a nomogram combining radiomics and BI-RADS. Sci Rep 2019; 9:11921.
15. Antropova N, Huynh BQ, Giger ML. A deep feature fusion methodology for breast cancer diagnosis demonstrated on three imaging modality datasets. Med Phys 2017; 44:S162–S171.
16. Xie T, Wang Z, Zhao Q, et al. Machine learning–based analysis of MR multiparametric radiomics for the subtype classification of breast cancer. Front Oncol 2019; 9:505.
17. Leithner D, Bernard-Davila B, Martinez DF, et al. Radiomic signatures derived from diffusion-weighted imaging for the assessment of breast cancer receptor status and molecular subtypes. Mol Imaging Biol 2020; 22:453–461.
18. Ma W, Zhao Y, Ji Y, et al. Breast cancer subtype prediction by mammographic radiomic features. Asian Radiol 2019; 26:196–201.
19. Li H, Zhu Y, Burnside ES, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer 2016; 2:pii:16012.
20. Xiong Q, Zhou X, Liu Z, et al. Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy. Clin Transl Oncol 2020; 22:50–59.
21. Antunovic L, De Sanctis R, Cozzi L, et al. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2019; 46:1468–1477.
22. Liu Z, Li Z, Qiu J, et al. Radiomics of multiparametric MRI for pre-treatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res 2019; 25:3538–3547.
23. Park H, Lim Y, Ko ES, et al. Radiomics signature on magnetic resonance imaging: association with disease-free survival in patients with invasive breast cancer. Clin Cancer Res 2018; 24:4705–4714.
24. Drukker K, Li H, Antropova N, Edwards A, Papaioannou J, Giger ML. Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival “early on” in neoadjuvant treatment of breast cancer. *Cancer Imaging* 2018; 18:12.

25. Braman NM, Etesami M, Prasanna P, et al. Erratum to: intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. *Breast Cancer Res* 2017; 19:80.

26. Ha S, Park S, Bang JI, Kim EK, Lee HY. Metabolic radiomics for pretreatment 18F-FDG PET/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neoadjuvant chemotherapy, and prognosis. *Sci Rep* 2017; 7:1556.

27. Li H, Zhu Y, Burnside ES, et al. MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, Oncotype DX, and PAM50 gene assays. *Radiology* 2016; 281:382–391.

28. American College of Radiology. *ACR BI-RADS® ultrasound*. In: *ACR BI-RADS® Atlas: Breast Imaging Reporting and Data System*. Reston, VA: American College of Radiology; 2013.

29. Koelliker SL, Chung MA, Mainiero MB, Steinhoff MM, Cady B. Axillary lymph nodes: US-guided fine-needle aspiration for initial staging of breast cancer-correlation with primary tumor size. *Radiology* 2018; 246:81–89.

30. Ouldamer L, Arbion F, Balagry A, Fourquet F, Marret H, Body G. Validation of a breast cancer nomogram for predicting nonsentinel node metastases after minimal sentinel node involvement: validation of the Helsinki breast nomogram. *Breast* 2013; 22:787–792.

31. Zou H, Hastie T. Addendum: regularization and variable selection via the elastic net. *J R Stat Soc B* 2005; 67:301–320.

32. Klar M, Foddi M, Markert S, Gitsch G, Sticheler E, Watermann D. Good prediction of the likelihood for sentinel lymph node metastasis by using the MSKCC nomogram in a German breast cancer population. *Ann Surg Oncol* 2009; 16:1136–1142.

33. Wu JL, Tseng HS, Yang LH, et al. Prediction of axillary lymph node metastases in breast cancer patients based on pathologic information of the primary tumor. *Med Sci Monit* 2014; 20:577–581.

34. Marrazzo A, Boscaino G, Marrazzo E, Taormina P, Toesca A. Breast cancer subtypes can be determinant in the decision making process to avoid surgical axillary staging: a retrospective cohort study. *Int J Surg* 2015; 21:156–161.

35. Bevilacqua JL, Kattan MW, Fey JV, Cody HS III, Borgen PI, Van Zee KJ. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. *J Clin Oncol* 2007; 25:3670–3679.

36. Xie F, Yang H, Wang S, et al. A logistic regression model for predicting axillary lymph nodemetastases in early breast carcinoma patients. *Sensors* 2012; 12:9936–9950.

37. Dong Y, Feng Q, Yang W, et al. Preoperative prediction of sentinel lymph node metastasis in breast cancer based on radiomics of T2-weighted fat-suppression and diffusion-weighted MRI. *Eur Radiol* 2018; 28:382–391.

38. Han L, Zhu Y, Liu Z, et al. Radiomic nomogram for prediction of axillary lymph node metastasis in breast cancer. *Eur Radiol* 2019; 29:3820–3829.

39. Liu C, Ding J, Spuhler K, et al. Preoperative prediction of sentinel lymph node metastasis in breast cancer by radiomic signatures from dynamic contrast-enhanced MRI. *Magn Reson Imaging* 2019; 50:7–14.

40. Yang J, Wang T, Yang L, et al. Preoperative prediction of axillary lymph node metastasis in breast cancer using mammography-based radiomics method. *Sci Rep* 2019; 9:3429.

41. Cui X, Wang N, Zhao Y, et al. Preoperative prediction of axillary lymph node metastasis in breast cancer using radiomics features of DCE-MRI. *Sci Rep* 2019; 9:2240.

42. Yu FH, Wang JX, Ye XH, Deng J, Hang J, Yang B. Ultrasound-based radiomics nomogram: a potential biomarker to predict axillary lymph node metastasis in early-stage invasive breast cancer. *Eur J Radiol* 2019; 119:108658.